Abstract
RMP-7, a bradykinin analog, has been shown to selectively open the blood-tumor barrier for the delivery of chemotherapeutic drugs to brain tumors. In contrast to bradykinin, RMP-7 has no hypotensive effects and has been approved for human use. This study was initiated to determine whether RMP-7 would open the blood-tumor barrier to virus vectors encoding tumor-killing genes in an experimental model. The herpes virus vector used, hrR3, which encodes virus thymidine kinase gene and the lacZ reporter gene, is defective in a gene encoding ribonucleotide reductase, replicates selectively in dividing tumor cells and not in postmitotic neural cells. It was determined that an optimum dose of RMP-7 (1.5–3.0 μg/kg over 10–15 minutes) enhanced viral delivery to brain tumors in rats bearing intracranial 9 L gliosarcomas when infused through the carotid artery immediately prior to virus vector application. Maximum expression of the lacZ reporter gene occurred at 3 days after intracarotid infusion. By 8 days, transgene expression was largely confined to tumor foci away from the main tumor mass. Viral delivery was essentially specific to tumor cells, with little transgene expression elsewhere in the brain. Minimal uptake and pathology was noted in the kidney, spleen, and liver. These findings indicate that intracarotid delivery of RMP-7 can augment the selective delivery of virus vectors to brain tumors in an experimental rat model, with the potential for application to human brain tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barnett, F., Rainov, N., Ikeda, K. et al. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther 6, 14–20 (1999). https://doi.org/10.1038/sj.cgt.7700003
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700003
Keywords
This article is cited by
-
Oncolytic virotherapy
Nature Biotechnology (2012)
-
Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life
Journal of Translational Medicine (2009)
-
Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure
Gene Therapy (2004)
-
Cancer gene therapy: an awkward adolescence
Cancer Gene Therapy (2003)
-
Quantitation of HSV mass distribution in a rodent brain tumor model
Gene Therapy (2000)